Pfizer is currently trading at Rs. 1772.00, up by 105.45 points or 6.33% from its previous closing of Rs. 1666.55 on the BSE.
The scrip opened at Rs. 1697.00 and has touched a high and low of Rs. 1785.80 and Rs. 1697.00 respectively. So far 2,484 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 2055.00 on 09-Sep-2016 and a 52 week low of Rs. 1641.00 on 30-May-2017.
Last one week high and low of the scrip stood at Rs. 1785.80 and Rs. 1641.00 respectively. The current market cap of the company is Rs. 8,106.50 crore.
The promoters holding in the company stood at 63.92%, while Institutions and Non-Institutions held 13.42% and 22.66% respectively.
Pfizer has entered into an acquisition agreement with AstraZeneca AB, Sweden (AstraZeneca), pursuant to which the brand ‘Neksium’ is being acquired by the company in India for a consideration of Rs 75 crore, subject to completion of necessary conditions precedent. Neksium (esomeprazole) complements the company’s existing product portfolio in the gastrointestinal (GI) therapeutic area.
Earlier in January, the company had entered into a Delegation of Authority with AstraZeneca Pharma India, pursuant to which AstraZeneca has granted certain authority to the company to conduct certain activities in India.
Pfizer has produced innovative breakthroughs in a wide range of research areas, including depression, erectile dysfunction, high cholesterol, HIV infection, hypertension, bacterial infections and systemic fungal infections.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1797.80 |
Dr. Reddys Lab | 1213.90 |
Cipla | 1486.30 |
Lupin | 2069.95 |
Zydus Lifesciences | 948.70 |
View more.. |